Momenta Pharmaceuticals, Inc.  

(Public, NASDAQ:MNTA)   Watch this stock  
Find more results for MNTA
+0.30 (2.63%)
After Hours: 11.69 0.00 (0.00%)
Sep 30, 4:59PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.30 - 11.76
52 week 7.86 - 18.85
Open 11.44
Vol / Avg. 354,529.00/686,865.00
Mkt cap 800.29M
P/E     -
Div/yield     -
EPS -1.53
Shares 70.98M
Beta 1.97
Inst. own 84%
Nov 2, 2016
Q3 2016 Momenta Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 7, 2016
Momenta Pharmaceuticals Inc at Wells Fargo Securities Healthcare Conference
Aug 4, 2016
Q2 2016 Momenta Pharmaceuticals Inc Earnings Call
Aug 4, 2016
Q2 2016 Momenta Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -79.40% -92.93%
Operating margin -81.87% -94.18%
EBITD margin - -84.14%
Return on average assets -19.55% -24.60%
Return on average equity -24.54% -28.91%
Employees 258 -
CDP Score - -


675 W Kendall St
CAMBRIDGE, MA 02142-1110
United States - Map
+1-617-4919700 (Phone)
+1-617-6210431 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.

Officers and directors

James R. Sulat Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Craig A. Wheeler President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ganesh Venkataraman Kaundinya Ph.D. Co-Founder, Senior Vice President - Research, Chief Scientific Officer
Age: 49
Bio & Compensation  - Reuters
Richard P. Shea Chief Financial Officer, Senior Vice President
Age: 64
Bio & Compensation  - Reuters
Matthew P. Ottmer Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
Bruce A. Leicher Senior Vice President, General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
Jo-Ann Beltramello Senior Vice President - Human Resources
Bio & Compensation  - Reuters
James Anderson Ph.D. Senior Vice President - Pharmaceutical Sciences
Bio & Compensation  - Reuters
Ian D. Fier Senior Vice President - Program and Project Management
Age: 43
Bio & Compensation  - Reuters
Young Kwon Ph.D. Senior Vice President - Corporate Development and Strategy
Bio & Compensation  - Reuters